Northland Securities Lowers Earnings Estimates for Brainsway

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Investment analysts at Northland Securities decreased their FY2025 earnings per share estimates for shares of Brainsway in a research report issued on Wednesday, March 4th. Northland Securities analyst C. Byrnes now forecasts that the company will post earnings of $0.09 per share for the year, down from their prior estimate of $0.17. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. Northland Securities also issued estimates for Brainsway’s Q4 2025 earnings at $0.02 EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.04 EPS and Q4 2026 earnings at $0.04 EPS.

A number of other equities research analysts also recently commented on BWAY. HC Wainwright boosted their target price on Brainsway from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Wall Street Zen downgraded Brainsway from a “buy” rating to a “hold” rating in a research note on Friday, January 23rd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Brainsway in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $15.00.

Brainsway Stock Down 2.2%

BWAY opened at $12.34 on Friday. The company has a market capitalization of $483.97 million, a PE ratio of 82.27 and a beta of 1.20. The firm has a 50-day simple moving average of $11.75 and a two-hundred day simple moving average of $9.32. Brainsway has a 52 week low of $3.92 and a 52 week high of $13.31.

Institutional Investors Weigh In On Brainsway

Several large investors have recently added to or reduced their stakes in BWAY. Goldman Sachs Group Inc. boosted its holdings in shares of Brainsway by 2.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 25,738 shares of the company’s stock worth $490,000 after purchasing an additional 589 shares during the period. Man Group plc raised its holdings in Brainsway by 4.5% during the 4th quarter. Man Group plc now owns 18,027 shares of the company’s stock valued at $343,000 after buying an additional 782 shares during the period. NewEdge Advisors LLC lifted its position in Brainsway by 7.4% in the third quarter. NewEdge Advisors LLC now owns 28,629 shares of the company’s stock worth $431,000 after buying an additional 1,964 shares during the last quarter. Zuckerman Investment Group LLC boosted its stake in Brainsway by 5.3% during the third quarter. Zuckerman Investment Group LLC now owns 40,000 shares of the company’s stock worth $603,000 after buying an additional 2,000 shares during the period. Finally, Palumbo Wealth Management LLC boosted its stake in Brainsway by 37.9% during the fourth quarter. Palumbo Wealth Management LLC now owns 16,320 shares of the company’s stock worth $310,000 after buying an additional 4,483 shares during the period. 30.11% of the stock is owned by institutional investors.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.